Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 4NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Rectal Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma 1

Interventions

fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 8Cyclosporine 7Cyclophosphamide 7Antilymphocyte Serum 6Filgrastim 5Busulfan 5sargramostim 4Methylprednisolone 4Methotrexate 4Cytarabine 4Tacrolimus 3Radiotherapy 3Mycophenolic Acid 3Imatinib Mesylate 3Etoposide 3Vorinostat 2Sunitinib 2Interferon-alpha 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Decitabine 2Dasatinib 2Carboplatin 2Analgesia 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tipifarnib 1temsirolimus 1tanespimycin 1perifosine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Accelerated Phase × Dasatinib × Clear all
NCT01426334 2014-04-02

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

National Cancer Institute (NCI)

Phase 1 Terminated
4 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00316953 2013-02-05

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

National Cancer Institute (NCI)

Phase 1 Completed
48 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡